The race to commercialize brain-computer interface (BCI) technology is accelerating rapidly in China, fueled by a massive new injection of capital into one of the sector’s leading startups. Shanghai StairMed Technology announced on April 2, 2026, that it had closed a strategic financing round of 500 million yuan (approximately $73 million).
The funding round is particularly notable for its lead investors. Alibaba spearheaded the investment, marking a significant strategic bet by the e-commerce and cloud computing giant on the future of neurotechnology. Even more striking is the participation of Tencent, making this a rare instance where China’s two largest tech conglomerates have co-invested in a BCI venture. This combined backing from Alibaba and Tencent signals a profound industry consensus on the long-term potential of human-machine interaction.
StairMed, founded in 2021, has quickly established itself as a formidable competitor in the global BCI landscape. The company has focused on developing proprietary technologies across the entire BCI stack, including ultra-flexible electrodes that are as fine as one-hundredth the width of a human hair, sophisticated algorithms, and specialized surgical robotics. Crucially, StairMed claims to have developed the world’s smallest wireless brain-machine interface (BMI) implant.
The company has already achieved significant clinical milestones. In 2025, StairMed completed China’s first prospective clinical trial for an invasive BMI. Furthermore, its product has been granted access to the National Medical Products Administration’s (NMPA) Green Channel for Innovative Medical Devices, a designation that expedites the regulatory review process for breakthrough technologies.
With the new $73 million war chest, StairMed is poised to significantly scale its clinical operations. The company has set an aggressive target to implant its device in 40 patients by the end of 2026. This ambitious timeline places StairMed in direct competition with Western BCI developers, most notably Elon Musk’s Neuralink, which is also targeting high-volume production and expanded human trials in 2026.
Li Xue, founder of StairMed, emphasized the strategic nature of the partnerships with Alibaba and Tencent. “BMI is not only an emerging medical technology, but also a point of convergence between life sciences and information technology,” Li stated. “The deep expertise of these industry leaders in multi-modal large models, computing infrastructure, intelligent hardware, and ecosystem development aligns closely with StairMed’s strengths in BMI hardware and clinical translation.”
The investment in StairMed must be viewed within the broader context of China’s national technology strategy. Beijing has explicitly listed BCIs as a core strategic priority, placing the technology on par with quantum computing and nuclear fusion. In mid-March 2026, China became the first country to approve BCIs as invasive medical devices for commercial use, creating a clear regulatory pathway for companies like StairMed and its domestic rival, state-backed NeuCyber Neurotec.
As StairMed pushes toward its goal of 40 patient implants this year, the company is not just advancing medical science; it is carrying the banner for China’s ambition to lead the world in the next frontier of human-computer integration.